| 臺大學術典藏 |
2020-07-09T02:57:01Z |
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer
|
Chen B.-B.;Lu Y.-S.;Lin C.-H.;Chen W.-W.;Wu P.-F.;Hsu C.-Y.;Chih-Wei Yu;Wei S.-Y.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Lu Y.-S.; Lin C.-H.; Chen W.-W.; Wu P.-F.; Hsu C.-Y.; CHIH-WEI YU; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-09T02:57:00Z |
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer
|
Chen B.-B.;Lu Y.-S.;Chih-Wei Yu;Lin C.-H.;Chen T.W.-W.;Wei S.-Y.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Lu Y.-S.; CHIH-WEI YU; Lin C.-H.; Chen T.W.-W.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
I�eB kinases increase Myc protein stability and enhance progression of breast cancer cells
|
Yeh P.-Y ;Lu Y.-S ;Da-Liang Ou ;Cheng A.-L.; Yeh P.-Y; Lu Y.-S; DA-LIANG OU; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:28:22Z |
The detection and identification of saliva in forensic samples by RT-LAMP
|
Linacre A.; Hsieh H.-M.; Tsai L.-C.;Su C.-W.;James Chun-I Lee;Lu Y.-S.;Chen H.-C.;Lin Y.-C.;Linacre A.;Hsieh H.-M.; Tsai L.-C.; Su C.-W.; JAMES CHUN-I LEE; Lu Y.-S.; Chen H.-C.; Lin Y.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H;Cheng A.-L;Hsu C;Chih-Hsin Yang;Lu Y.-S;Lin C.-C;Bu C.-F;Yeh K.-H.; Hsu C.-H; Cheng A.-L; Hsu C; CHIH-HSIN YANG; Lu Y.-S; Lin C.-C; Bu C.-F; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C;Shen Y.-C;Chih-Hsin Yang;Yeh K.-H;Lu Y.-S;Hsu C.-H;Liu H.-T;Li C.-C;Chen J.-S;Wu C.-Y;Cheng A.-L.; Hsu C; Shen Y.-C; CHIH-HSIN YANG; Yeh K.-H; Lu Y.-S; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S;Hsu C;Li C.-C;Kuo S.-H;Yeh K.-H;Chih-Hsin Yang;Hsu C.-H;Wu C.-Y;Cheng A.-L.; Lu Y.-S; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; CHIH-HSIN YANG; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Lu Y.S;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Chih-Hsin Yang;Cheng A.L.; Yeh K.H; Lu Y.S; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; CHIH-HSIN YANG; Cheng A.L. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:16Z |
O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers
|
Wu P.-F;Kuo K.-T;Kuo L.-T;Lin Y.-T;Lee W.-C;Lu Y.-S;Chih-Hsin Yang;Wu R.-M;Tu Y.-K;Tasi J.-C;Tseng H.-M;Tseng S.-H;Cheng A.-L;Lin C.-H.; Wu P.-F; Kuo K.-T; Kuo L.-T; Lin Y.-T; Lee W.-C; Lu Y.-S; CHIH-HSIN YANG; Wu R.-M; Tu Y.-K; Tasi J.-C; Tseng H.-M; Tseng S.-H; Cheng A.-L; Lin C.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country
|
Chen I.-C; Wu P.-F; Kuo S.-H; Chen C.-J; Lu Y.-S; Cheng A.-L.; Cheng A.-L.;Lu Y.-S;Chen C.-J;Kuo S.-H;Wu P.-F;Chen I.-C;Chen W.-W;Kuo K.-T;Hsiung C.-N;Chang D.-Y;Kuo W.-H;Chih-Hsin Yang;Huang C.-S;Lee J.-H;Shen C.-Y;Lin C.-H; Lin C.-H; Shen C.-Y; Lee J.-H; Huang C.-S; CHIH-HSIN YANG; Kuo W.-H; Chang D.-Y; Hsiung C.-N; Kuo K.-T; Chen W.-W |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.;Yeh P.-Y.;Gao M.;Chen C.-W.;Yeh L.-C.;Feng W.-C.;Kuo S.-H.;Chih-Hung Hsu;Lu Y.-S.;Cheng A.-L.; Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; Kuo S.-H.; CHIH-HUNG HSU; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:26Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; CHIH-HUNG HSU; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. ;Chih-Hung Hsu ;Chen L.-T. ;Lu Y.-S. ;Lin C.-H. ;Yeh P.-Y. ;Jeng H.-J. ;Gao M. ;Yeh K.-H. ;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:30Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma
|
Chiun Hsu;Huang C.-S.;Chao T.-Y.;Lu Y.-S.;Bu C.-F.;Chen M.M.;Chang K.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J.;Wang C.-C.;Cheng A.-L.;Chiun Hsu;Lu Y.-S.;Chang M.-C.;Lin J.-T.;Wang H.-P.;Shiah H.-S.;Liu T.-W.;Chang J.-Y.;Whang-Peng J.;Chen L.-T.; Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Chiun Hsu; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Chiun Hsu; Cheng A.-L. |
